ft above-knee DVT – started on UFH (about 28 000 units/24h for therapeutic PTT) Immediately after 4 days of UFH: Worsening bilateral limb-threatening DVTs – fondaparinux 7.5 mg die x 16 months, followed by Apixabannear resolution of D-dimers Duplex three months post: bilateral partial recanalizationAPS: antiphospholipid syndrome; PE: pulmonary emboli; LMWH: low-molecular-weight heparin; HELLP: hemolysis, elevated liver enzymes, and low platelets; TIA: transient ischemic attack; DVT: deep vein thrombosis; UFH: unfractionated heparin; PTT: partial thromboplastin time; IVC: inferior vena cavaABSTRACT935 of|PB1274|May-Thurner Syndrome-associated Deep Vein Thrombosis: Is Oral Anticoagulation the Novel Method F.A. Lo Tan Tock Seng Hospital, Singapore, Singapore Background: May-Thurner Syndrome (MTS) has been reported in 1 out of five sufferers presenting with left ilio-femoral deep vein thrombosis (DVT). Anticoagulation, catheter-directed thrombolysis (CDT) with stenting, CB1 Antagonist custom synthesis thrombectomy, and bypass surgery are amongst the therapy possibilities. Aims: To follow-up the clinical outcomes of individuals with MTSassociated DVT who received different therapy options in a span of 4 years. Techniques: Inclusion criteria had been adult patients followed-up at our institution’s Vascular Medicine Clinic with MTS detected by computed tomography (CT) scan, and followed-up for a minimum of two years with or without the need of repeat CT scan. We excluded individuals who had been followed-up inside a non-Vascular Medicine specialty clinics, and these with interior vena cava (IVC) filters. 3 treatment groups had been identified: (A) anticoagulation (warfarin or direct oral anticoagulation), (B) CDT with stenting, or (C) graft bypass. Results: Fifteen (15) sufferers have been identified. One patient was excluded as a result of presence of IVC filter, and a single patient died while around the second year of follow-up. Group A had eight patients, 3 in Group B, and two in Group C (n = 13). Right after 4 years of follow-up, repeat CT scans in Group A showed documented clearance of DVT in 6 individuals, Group B had stable stents with no evidence of DVT in the three circumstances, though one particular patient in Group C showed graft patency. Post-thrombotic syndrome was observed in two individuals in Group A, and none in Groups B and C. No bleeding complications had been noticed in all treatment groups. Conclusions: As catheter-directed therapy appears to be a additional appropriate interventional strategy when compared with graft bypass surgery; oral anticoagulation therapy for MTS-associated DVT might be supplied to individuals as an alternative. This can be specially suitable for sufferers that have high perioperative risk, or for all those who make a decision not to undergo interventional or surgical therapy.PB1275|Heparin Therapeutic Range for 5 aPTT Reagents in Plasma and One Point of Care E. Cortina-de la Rosa; K.G. Cort -Cort ; M.O. RomeroArroyo; F.A. Grimaldo-G ez; M.M. Salcedo-Hern dez; A. Arrieta-Alvarado; A. Ram ez-Hern dez; S. V quez-Olvera; R. Izaguirre- ila National Institute of Cardiology Ignacio Ch ez, Mexico City, Mexico Background: Due unfractionated heparin (UFH) has an unstable pharmacokinetics, it COX-2 Modulator web demands close monitoring that suggests a challenge for medical consideration. Probably the most applied assay to monitoring the UFHs therapy has been the activated Partial Thromboplastin Time (aPTT). It has been suggested unique strategies to establish heparin therapeutic ranges (HTR) for the ideal use of aPTT to monitoring the UFH therapy. Aims: To get the HTR for 5 various aPTT reagents and from a point of care (
